| Eylea (aflibercept intravitreal) / Bayer, Regeneron |
NCT02126904: Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept |
|
|
| Unknown status | N/A | 200 | Japan | IVA group | Yokohama City University Medical Center, Novartis Pharmaceuticals | The Injection Burden | 10/13 | | | |
NCT01918371: A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema |
|
|
| Completed | N/A | 323 | US | Anti-VEGF, Avastin®, Lucentis®, Eylea® | Allergan | Retinal Vein Occlusion, Macular Edema | 09/14 | 09/14 | | |
NCT02291887: Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept |
|
|
| Completed | N/A | 13 | US | Ranibizumab, Lucentis, Aflibercept, Eylea | Associated Retinal Consultants, Michigan, Genentech, Inc. | Age-Related Macular Degeneration | 07/15 | 07/15 | | |
NCT02005133: A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics |
|
|
| Terminated | N/A | 188 | Europe | | Novartis Pharmaceuticals | Wet Age-related Macular Degeneration | 10/15 | 10/15 | | |
| Completed | N/A | 40 | US | Intravitreal Aflibercept Injection | MidAtlantic Retina, Regeneron Pharmaceuticals | Age-Related Macular Degeneration, Macular Degeneration | 03/16 | 03/16 | | |
|
NCT02541084: Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan |
|
|
| Completed | N/A | 72 | Japan | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 03/16 | 07/16 | | |
NCT02585401: Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada |
|
|
| Completed | N/A | 99 | Canada | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME) | 03/16 | 05/16 | | |
NCT01756261: EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan |
|
|
| Completed | N/A | 757 | Japan | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Macular Degeneration | 07/16 | 02/17 | | |
NCT02615496: Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept |
|
|
| Completed | N/A | 716 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, RTI Health Solutions | Macular Degeneration | 09/16 | 01/17 | | |
TITAN, NCT02321241: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD |
|
|
| Completed | N/A | 236 | Europe | Aflibercept (EYLEA, BAY-86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 01/17 | 08/17 | | |
PERSEUS, NCT01914380: Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration |
|
|
| Completed | N/A | 988 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Age-related Macular Degeneration | 03/17 | 03/17 | | |
NCT02956330: Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201 |
|
|
| Completed | N/A | 20 | US | | Clearside Biomedical, Inc. | Macular Edema, Retinal Vein Occlusion | 04/17 | 04/17 | | |
NCT01714115: Use of Eylea for the Treatment of an Optic Nerve Hemangioma |
|
|
| No Longer Available | N/A | | US | Aflibercept, Eylea, VEGF Trap-Eye | Vitreous -Retina- Macula Consultants of New York, Regeneron Pharmaceuticals | Retinal Hemangioma | | | | |
PEGASUS, NCT02540369: To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada. |
|
|
| Completed | N/A | 2150 | Canada | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 09/17 | 01/18 | | |
| Completed | N/A | 425 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Eye Diseases | 11/17 | 11/17 | | |
RETRO CRVO, NCT02645747: Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion |
|
|
| Completed | N/A | 126 | Europe | Aflibercept (Eylea, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Retinal Vein Occlusion | 12/17 | 12/17 | | |
INSIGHT, NCT03278262: The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting |
|
|
| Completed | N/A | 2312 | Europe | Aflibercept (Eylea, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 12/17 | 12/17 | | |
NCT02457026: Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD |
|
|
| Withdrawn | N/A | 0 | US | Aflibercept, Eylea, Triamcinolone Acetonide, Triesence, Verteporfin, Visudyne | Duke University, Bausch & Lomb Incorporated | Neovascular Age-related Macular Degeneration | 01/18 | 01/18 | | |
NCT02260687: Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization |
|
|
| Completed | N/A | 353 | Japan | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Choroidal Neovascularization | 04/18 | 08/18 | | |
JPMS-CRVO, NCT02040220: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO) |
|
|
| Completed | N/A | 385 | Japan | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Retinal Vein Occlusion | 06/18 | 11/18 | | |
ASTERIA, NCT03382587: Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients |
|
|
| Completed | N/A | 163 | Europe | Aflibercept (Eylea, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Age-related Macular Degeneration | 11/18 | 11/18 | | |
GALAXY, NCT03521895: An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies |
|
|
| Completed | N/A | 1000 | Europe | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Bayer | Macular Degeneration | 11/18 | 11/18 | | |
NCT01756248: EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan |
|
|
| Completed | N/A | 3872 | Japan | Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Macular Degeneration | 12/18 | 05/19 | | |
| Completed | N/A | 3206 | RoW | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Macular Degeneration | 12/18 | 12/18 | | |
REALE, NCT03411941: Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD) |
|
|
| Completed | N/A | 116 | Europe | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Macular Degeneration | 03/19 | 03/19 | | |
PERSEUS-IT, NCT02289924: Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy |
|
|
| Completed | N/A | 912 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 03/19 | 07/19 | | |
| Completed | N/A | 593 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 04/19 | 04/19 | | |
NCT02425501: Special Drug Use Investigation of EYLEA for Diabetic Macular Edema |
|
|
| Completed | N/A | 646 | Japan | Aflibercept (Eylea, BAY86-5321) | Bayer | Macular Edema | 04/19 | 08/19 | | |
DRAKO, NCT02850263: A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema |
|
|
| Completed | N/A | 750 | Europe | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321), Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05) | Bayer | Macular Edema | 05/19 | 11/20 | | |
PERSEUS-GR, NCT02821247: Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece |
|
|
| Completed | N/A | 119 | Europe | Aflibercept (Eylea, BAY86-5321), VEGF Trap-Eye | Bayer | Choroidal Neovascularization, Macular Degeneration | 07/19 | 12/19 | | |
APOLLON, NCT02924311: Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema |
|
|
| Completed | N/A | 402 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Diabetic Retinopathy | 08/19 | 12/19 | | |
NCT04067583: A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe |
|
|
| Completed | N/A | 454 | Europe | Physician questionnaire | Bayer | Ophthalmology, Macular Degeneration | 04/20 | 04/20 | | |
MODEVA, NCT02874859: Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema |
|
|
| Completed | N/A | 49 | Europe | | Lille Catholic University, Bayer | Diabetic Macular Edema | 08/20 | 08/20 | | |
AQUILA, NCT03470103: A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America |
|
|
| Completed | N/A | 643 | RoW | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Bayer | Macular Degeneration | 09/20 | 01/21 | | |
NCT05110209: Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry) |
|
|
| Completed | N/A | 331541 | US | Aflibercept, EYLEA®, Ranibizumab, LUCENTIS®, Bevacizumab, AVASTIN®; off-label use | Novartis Pharmaceuticals | Age-related Macular Degeneration (AMD) | 11/20 | 11/20 | | |
NCT05146687: Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health) |
|
|
| Completed | N/A | 369600 | US | Aflibercept, EYLEA®, Ranibizumab, LUCENTIS®, Bevacizumab, AVASTIN®; off-label use | Novartis Pharmaceuticals | Age-related Macular Degeneration (AMD) | 12/20 | 12/20 | | |
BELUGA, NCT04641234: A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD). |
|
|
| Completed | N/A | 330 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer | Neovascular Age-related Macular Degeneration | 06/21 | 06/21 | | |
AURIGA, NCT03161912: A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease |
|
|
| Completed | N/A | 2481 | Europe, RoW | Aflibercept (Eylea, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Macular Edema | 09/21 | 12/21 | | |
NAAVA, NCT04137120: Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice |
|
|
| Completed | N/A | 73 | RoW | Aflibercept (BAY86-5321, Eylea), Eylea®; Eylia®; Wetlia®; VEGF Trap-Eye | Bayer | Retinal Disease | 08/22 | 02/23 | | |
REALM, NCT04524910: A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV) |
|
|
| Completed | N/A | 28 | Canada | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer | Myopic Choroidal Neovascularization | 10/22 | 11/22 | | |
NCT03290794: Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice |
|
|
| Completed | N/A | 100 | RoW | Aflibercept (Eylea, BAY86-5321) | Bayer | Wet Age-related Macular Degeneration | 11/22 | 05/23 | | |
HERMES Study, NCT02880644: Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept |
|
|
| Completed | N/A | 65 | Europe | | Centre Hospitalier Intercommunal Creteil, Bayer, Association Clinique Thérapeutique Infantile du val de Marne | Retinal Vein Occlusion | 11/22 | 11/22 | | |
NCT05791695: A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022 |
|
|
| Completed | N/A | 155413 | US | Non Applicable | Regeneron Pharmaceuticals, Bayer | Intraocular Inflammation, Suspected Endophthalmitis | 12/22 | 09/23 | | |
NCT03297684: Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection |
|
|
| Active, not recruiting | N/A | 40 | US | Aflibercept Injection [Eylea] | Advanced Eye Research Associates | Diabetic Macular Edema | 12/22 | 12/22 | | |
| Active, not recruiting | N/A | 49 | Europe | | Centre Hospitalier Intercommunal Creteil, Bayer | AMD, Exudative Macular Degeneration | 01/23 | 07/23 | | |
ANDROMEDA, NCT03714308: Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina. |
|
|
| Completed | N/A | 554 | Europe | Ivt. Aflibercept (Eylea, BAY86-5321) | Bayer | Macular Degeneration | 03/23 | 05/23 | | |
RAZORBILL, NCT04662944: A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections |
|
|
| Completed | N/A | 494 | Europe, Canada | brolucizumab, ranibizumab, aflibercept | Novartis Pharmaceuticals | Neovascular Age-Related Macular Degeneration | 06/23 | 06/23 | | |
XTEND, NCT03939767: Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease |
|
|
| Completed | N/A | 1563 | Europe, Canada, RoW | Aflibercept (Eylea, BAY86-5321) | Bayer | Wet Age-related Macular Degeneration | 07/23 | 10/23 | | |
NCT06315556: An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK) |
|
|
| Recruiting | N/A | 200 | Europe | Aflibercept (Eylea) | Bayer | Retinopathy of Prematurity, Preterm Infants | 03/27 | 04/27 | | |
PULSOV, NCT04793100: Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections |
|
|
| Active, not recruiting | N/A | 60 | Europe | Ophthalmologic exam at inclusion and 12 months after CRVO, Treatment standardization with aflibercept | Fondation Ophtalmologique Adolphe de Rothschild, Bayer | Central Retinal Vein Occlusion | 03/25 | 03/25 | | |
SPECTRUM-US, NCT06398080: An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting |
|
|
| Not yet recruiting | N/A | 800 | NA | aflibercept 8 mg, EYLEA® HD | Regeneron Pharmaceuticals | Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment | 11/27 | 11/28 | | |
NCT05705258: A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity) |
|
|
| Recruiting | N/A | 75 | Japan | Aflibercept (Eylea, BAY86-5321) | Bayer | Retinopathy of Prematurity, Newborns, Infants | 04/26 | 03/27 | | |
NCT04519619: Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG) |
|
|
| Recruiting | N/A | 480 | Japan | Aflibercept (Eylea, BAY86-5321) | Bayer | Neovascular Glaucoma | 06/27 | 06/28 | | |
NCT06075147: The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema |
|
|
| Recruiting | N/A | 2500 | Europe, Canada, Japan, RoW | Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Bayer | Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME) | 10/27 | 01/28 | | |
